Andersen-Gill model for the end point RFS
| . | RFS . | ||
|---|---|---|---|
| Prognostic markers . | HR . | 95% CI . | P . | 
| Allogeneic HSCT | 0.23 | 0.11-0.51 | <.001 | 
| Autologous HSCT | 0.37 | 0.17-0.80 | .012 | 
| Log10(WBC) | 1.40 | 0.77-2.56 | .27 | 
| Log10(platelets) | 0.81 | 0.40-1.66 | .57 | 
| % BM blasts (difference 10%) | 0.94 | 0.82-1.08 | .40 | 
| Age (difference of 10 y) | 0.86 | 0.68-1.08 | .20 | 
| Abnormal karyotype | 0.73 | 0.38-1.40 | .35 | 
| . | RFS . | ||
|---|---|---|---|
| Prognostic markers . | HR . | 95% CI . | P . | 
| Allogeneic HSCT | 0.23 | 0.11-0.51 | <.001 | 
| Autologous HSCT | 0.37 | 0.17-0.80 | .012 | 
| Log10(WBC) | 1.40 | 0.77-2.56 | .27 | 
| Log10(platelets) | 0.81 | 0.40-1.66 | .57 | 
| % BM blasts (difference 10%) | 0.94 | 0.82-1.08 | .40 | 
| Age (difference of 10 y) | 0.86 | 0.68-1.08 | .20 | 
| Abnormal karyotype | 0.73 | 0.38-1.40 | .35 | 
WBC, white blood cell count.